新世紀醫療(01518.HK)中期經調整EBITDA升8.1%至2270萬元
格隆匯8月31日丨新世紀醫療(01518.HK)公佈中期業績,截至2021年6月30日止6個月,集團錄得收益人民幣2.858億元,與去年同期相比顯著增長31.9%。兒科服務收益迅速上升,與去年同期相比增長50.4%。
期內虧損收窄84.6%至人民幣4910萬元,截至2020年6月30日止六個月則為人民幣3.193億元。經調整期內虧損收窄39.2%至人民幣4170萬元,截至2020年6月30日止六個月則為人民幣6860萬元。
期內經調整EBITDA上升8.1%至人民幣2270萬元,截至2020年6月30日止六個月則為人民幣2100萬元。截至2021年6月30日止6個月已開業並且持續運營的醫療機構經調整EBITDA合計為人民幣6480萬元,與截至2020年6月30日止6個月的人民幣4380萬元相比,同比增長47.9%。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.